# Manish A. Shah

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/manish-a-shah/

## Facts

| Field | Value |
| --- | --- |
| Citations | 34,076 |
| Field | Gastric Cancer Management and Outcomes |
| h-index | 83 |
| i10-index | 232 |
| Last Known Institution | Cornell University |
| OpenAlex ID | https://openalex.org/A5089202777 |
| ORCID iD | https://orcid.org/0000-0002-6913-9655 |
| Works | 662 |

## Researcher papers

- [A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.](https://scholariq.org/papers/a-novel-gene-containing-a-trinucleotide-repeat-that-is-expanded-and-unstable-on/)
- [Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-versus-chemotherapy-alone-for-first-line/)
- [Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer](https://scholariq.org/papers/randomized-phase-iii-keynote-181-study-of-pembrolizumab-versus-chemotherapy-in/)
- [Chemotherapy Use, Performance Status, and Quality of Life at the End of Life](https://scholariq.org/papers/chemotherapy-use-performance-status-and-quality-of-life-at-the-end-of-life/)
- [Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus](https://scholariq.org/papers/efficacy-and-safety-of-pembrolizumab-for-heavily-pretreated-patients-with/)
- [Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-with-cisplatin-and-fluoropyrimidine-as-first-line-therapy-in/)

## Researcher topics

- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Gastrointestinal Tumor Research and Treatment](https://scholariq.org/topics/gastrointestinal-tumor-research-and-treatment/)

## Researcher university

- [Cornell University](https://scholariq.org/institutions/cornell-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.